These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3816548)

  • 1. Is there cost reduction potential for extended half-life cephalosporins?
    Scalley RD; Stuart CC
    Drug Intell Clin Pharm; 1986 Dec; 20(12):975-80. PubMed ID: 3816548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital.
    Woodward RS; Medoff G; Smith MD; Gray JL
    Am J Med; 1987 Nov; 83(5):817-23. PubMed ID: 3674089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of parenteral cephalosporin regulation on pharmacy costs.
    Ryan JL; Francese J
    Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods of controlling cephalosporin use in Canadian hospitals.
    Godin JP; Sketris IS; Merrett RA; Marrie TJ
    Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical antibiotic prophylaxis, patient morbidity, and cost reduction: a three-year study.
    Scalley RD; Irwin AD; Poduska PJ; Wolff AJ; Cochran RS
    Drug Intell Clin Pharm; 1987; 21(7-8):648-52. PubMed ID: 3608815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
    Tartaglione TA; Polk RE
    Drug Intell Clin Pharm; 1985 Mar; 19(3):188-98. PubMed ID: 3884304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the extended half-life second-generation cephalosporins in surgical prophylaxis.
    Rapp RP; Blue D
    Drug Intell Clin Pharm; 1985 Mar; 19(3):214-6. PubMed ID: 3979267
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of a cephalosporin education program--a pharmacy education program.
    Sohn CA; Wolter HA; McSweeney GW
    Drug Intell Clin Pharm; 1980 Apr; 14(4):272-7. PubMed ID: 10309192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing prophylactic antibiotic costs in cardiovascular surgery: the role of the clinical pharmacist.
    Peterson CD; Lake KD
    Drug Intell Clin Pharm; 1986 Feb; 20(2):134-7. PubMed ID: 3948689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing physician prescribing habits through a cost-effective first generation cephalosporin formulary.
    Cramer R; Wright C
    Hosp Pharm; 1989 Jan; 24(1):33-8. PubMed ID: 10312858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial impact of formulary revision of second-generation cephalosporins.
    Andrews JD; Hafting S
    Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacy U.R. cuts costs, drug use.
    Mosier RL
    Hosp Peer Rev; 1979 May; 4(5):70-2. PubMed ID: 10308905
    [No Abstract]   [Full Text] [Related]  

  • 15. Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population.
    Berman S; Byrns PJ; Bondy J; Smith PJ; Lezotte D
    Pediatrics; 1997 Oct; 100(4):585-92. PubMed ID: 9310510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended half-life, second-generation cephalosporin in surgical prophylaxis.
    Farchione LA
    Drug Intell Clin Pharm; 1985 Nov; 19(11):842-3. PubMed ID: 4064920
    [No Abstract]   [Full Text] [Related]  

  • 17. Automatic interchange policy for first-generation i.v. cephalosporins.
    Suzuki NT
    Am J Hosp Pharm; 1987 Mar; 44(3):505. PubMed ID: 3565404
    [No Abstract]   [Full Text] [Related]  

  • 18. A lab-pharmacy push to cut drug therapy costs.
    Rydzewski MM
    MLO Med Lab Obs; 1984 Oct; 16(10):63-4, 69. PubMed ID: 10268396
    [No Abstract]   [Full Text] [Related]  

  • 19. Savings achieved through cephalosporin surveillance.
    Katz E; Schlamowitz S
    Am J Hosp Pharm; 1978 Dec; 35(12):1521-3. PubMed ID: 717407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost containment of reconstituted parenteral antibiotics: personnel and supply costs associated with preparation, dispensing, and administration.
    Tanner DJ
    Rev Infect Dis; 1984; 6 Suppl 4():S924-37. PubMed ID: 6522928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.